This site is intended for healthcare professionals

HELIOS-A phase III study of vutrisiran positive for for the treatment of transthyretin-mediated (ATTR) amyloidosis with polyneuropathy. Alnylam Pharma

Read time: 1 mins
Last updated:8th Jan 2021
Published:8th Jan 2021
Condition: Transthyretin Amyloidosis (ATTR amyloidosis)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest